BRAF and neoplasm: As confirmed by Steinberg et al. it significantly decreased Tregs and depleted intratumoral MDSCs within the tumor microenvironment, and thus promoted tumor eradication in BRAF/PTEN genetically engineered mouse model treated with BRAF inhibitor (PLX4032).